ClinicalTrials.gg
Status unknownNCT03916107Updated Apr 16, 2019

Comparison of Different Surgical Treatments for Severe Ptosis Correction

An interventional study of Levator muscle and tarsus resection and Frontalis flap in Ptosis, Eyelid, sponsored by Shanghai Jiao Tong University School of Medicine. Status unknown at 1 site in China. Open to participants aged 3 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2019), so the status shown — last known as Enrolling by invitation — may be out of date.

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jan 2018, registered Apr 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
3 Years to 80 Years
Sex
All
01

Study summary

Main research purposes of this research is to compare the therapeutic effect and safety of the superior levator muscle shortening combined with the tarsus resection and the traditional frontal muscle flap in the correction of severe ptosis.

Aside of above we also tend to explore the dose-effect relationship between the amount of levator muscle shortened/ tarsus resection and postoperative ptosis correction amount.So as to develop a more critical and specific guidelines for clinical treatment of ptosis.

So during the research we will recruiting patients with severe ptosis and randomly divide them into levator muscle and tarsus group and frontal muscle flap group, and follow up those patient 6 months post operation so as to evaluate the amount of correction and the side-symptoms.

Read the detailed description

The ptosis is divided into light, medium and severe according to the difference in muscle strength of the upper levator muscle. According to the previous diagnosis and treatment criteria, for the mild and moderate ptosis, it is recommended to use the method of shortening or partial resection of the levator muscle. For severe patients, because the strength of the upper levator muscles are extremely weak, the function of the upper eye lid can only be reconstructed through the strength of the frontal muscles. So it is recommended to use the frontal muscle flap surgery for correct ptosis. However, compared with the levator levator shortening, the shortcoming of the frontal muscle suspension is to change the nature anatomical relationship of the upper eyelid, resulting in unnatural eye lid lines, obvious frontal lines, easy recurrence and other shortcomings. In the case, this therapy turns out not to be very satisfied.

Based on years of clinical experience in treating ptosis, our research team have tried to use the levator muscle shortening combined with the tarsus resection method for more than 10 years. We have successfully cured more than 1000 patients with severe ptosis and obtained good therapeutic effects. The results are summarized and the sequence is published in several international journals and is recognized by domestic and foreign counterparts. However, for the new procedure of levator muscle shortening combined with tarsus resection, there is currently no comparative study with traditional therapy, and it is impossible to objectively evaluate its efficacy. Secondly, how to improve the long-term effect of levator muscle shortening combined with tarsus resection, whether the eyelid morphology is satisfactory, and the recurrence rate has not been reported. In addition, because the tarsus plays an important role in the shape and function of the eye, including maintaining the function of the tarsus and keeping the cornea moist, etc., the effect of partial removal of the tarsus on the original tarsus function is also worthy of further investigation.

Based on the original clinical results, the project team designed a randomized controlled single-blind study to compare the efficacy and safety of the levator muscle shortening combined with the tarsal resection and the traditional frontal muscle flap in the correction of severe ptosis. At the same time, to explore the dose-effect relationship between the shortening of the levator muscle and the amount of tarsal resection and the amount of correction of the ptosis after operation, the surgical design is more precise and personalized, which provides a scientific basis for further development of clinical diagnosis and treatment guidelines.

02

Conditions studied

  • Ptosis, Eyelid

Browse trials for

Keywords

  • Ptosis
  • Frontalis flap
03

In context

Blepharoptosis

63 studies on the registry are indexed under Blepharoptosis; 16 are open to participants now.

This study's planned enrollment of 100 is above the median of 45 across 50 interventional studies indexed under Blepharoptosis.

Browse Blepharoptosis studies →

Lead sponsor

Shanghai Jiao Tong University School of Medicine is the lead sponsor of 370 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • unilateral ptosis patient
  • the levator muscle strength less than 4mm
  • primary surgery
  • older than 3 years
  • ocular rectus muscle of good strength;

Exclusion criteria

Exclusion Criteria:

  • patients who had undergone ptosis correction surgery
  • patients with neurological ptosis, senile ptosis or pseudo ptosis
  • patients with abnormal ocular function
  • patients with Marcus-Gunn syndromes
  • patients with severe systemic disease or intolerant to general anesthesia
  • patients or their parents cannot finish follow-up due to educational level or various other reasons.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Levator muscle and tarsus resection

    Procedure: Levator muscle and tarsus resection

  • Active comparator
    Frontal muscle flap

    Procedure: Frontalis flap

Interventions

  • ProcedureLevator muscle and tarsus resection

    Shortening the levator muscle with resection of tarsus to correct severe ptosis

  • ProcedureFrontalis flap

    Using frontal muscle flap to correct severe ptosis

06

What researchers measure

Primary outcomes

  1. levator muscle's strength

    Measuring the muscle strength: let the patient look straight ahead, the examiner presses the eyebrow arch horizontally with the thumb, interrupting the connection between the frontal muscle and the upper eyelids, and ask patient to look down. Then ask the patient to look up as much as they can, and the scale of this movement is the levator muscle strength. When a normal person does not use the frontal muscle, the average scale of the upper eye lids movement is 13.37±2.55mm. The muscle strength of the upper eye lids is generally divided into three levels. The good upper eye lids movement scale is 8mm, the medium is 4\~7mm, and the weak one is 0\~3mm.

    Time frame: 6 months post the treatment

  2. width of eyes

    Measure the width of eyes while doctor shall make sure patient avoid looking up or using the frontal muscle to lift eyelids.

    Time frame: 6 months post the treatment

  3. MRD (margin reflex distance)

    Measure the distance from the upper temporal margin to the point of reflection at the center of the cornea, while doctor shall make sure patient avoid looking up or using the frontal muscle to lift eyelids.

    Time frame: 6 months post the treatment

Secondary outcomes

  1. Numbers of patients not completely corrected

    Patients who are below: 1. overcorrection(could result in the inability to close the eye completely) 2. inadequate correction; 3. recurrence of ptosis; All above is based on outcome 1,2,3

    Time frame: 6 months post the treatment

  2. Numbers of patients having dry eye syndrome

    using OSDI test to see if patients have dry eye syndrome

    Time frame: 6 months post the treatment

  3. Numbers of patients having corneal injury

    corneal injury using topography to check

    Time frame: 6 months post the treatment

  4. Numbers of patients having orbital insufficiency

    orbital insufficiency, using new national standard visual acuity chart to test

    Time frame: 6 months post the treatment

  5. Numbers of patients having conjunctival prolapse;

    based on examination result using slit-lamp microscope

    Time frame: 6 months post the treatment

  6. Numbers of patients having trichiasis;

    based on examination result using slit-lamp microscope

    Time frame: 6 months post the treatment

  7. Numbers of patients having eye infection;

    based on examination result using slit-lamp microscope

    Time frame: 6 months post the treatment

07

Study locations

1 site
  • Shanghai Ninth People's Hospital, Affliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200011, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03916107
Responsible party
Qing-FengLi Li,MD (MD, PhD, Professor, Head of the Department of Plastic and Reconstructive Surgery, Shanghai 9th People'sHospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Apr 16, 2019
Start date
Jan 1, 2018
Primary completion
Dec 31, 2019 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
Apr 16, 2019

Study contacts

Jun Yang, MD, Phd
study director · Shanghai Ninth People's Hospital, Affliated to Shanghai Jiao Tong University School of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion